With a business model based on portfolio management, the new company backed by MPM Capital plans to de-risk novel cancer therapies for out-licensing upon proof-of-concept or other value-creating inflection points.
Privately held Cullinan Oncology LLC is launching with a $150m Series A financing, using a model of taking stand-alone cancer projects that other companies might turn down as too risky through Phase II proof-of-concept, and then – hopefully – monetizing them.
Backed by MPM Capital and F2 Ventures, Cullinan derives from the former’s UBS Oncology Impact Fund (IOF) as well as...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
